亚洲精品成人免费_91女神娇喘疯狂3p之夜_精品韩国一级久久_av毛片网_www超碰com_午夜视频体内射.COM.COM

ChinaBio  
ChinaBio? 的故事始于一次旅行... 2006年11月，我們的創(chuàng)始人Greg Scott先生第一次到訪中國(guó)。他為赴一次商務(wù)會(huì)面來(lái)到了上海張江高科技園。這次會(huì)議后，他簡(jiǎn)要走訪了這個(gè)占地面積25km2的園區(qū)，看到了羅氏、輝瑞、葛蘭素史克、禮來(lái)以及200多家早期生物技術(shù)公司，他就堅(jiān)信自己將再次來(lái)到中國(guó)。在美國(guó)擁有超過(guò)10年生物技術(shù)行業(yè)天使投資經(jīng)驗(yàn)的他相信中國(guó)將有"大事"發(fā)生，他決心一探究竟。

因此2007年1月下旬，他再次來(lái)到中國(guó)，計(jì)劃停留一周時(shí)間，只安排了2場(chǎng)會(huì)議。但到這周結(jié)束時(shí)他已經(jīng)進(jìn)行了30多次會(huì)議，他心里已經(jīng)播下了ChinaBio? 的種子。到了4月，ChinaBio? 在張江高科技園區(qū)藥谷大廈開(kāi)設(shè)了辦公室，招進(jìn)了第一位員工。當(dāng)時(shí)他常聽(tīng)說(shuō)鮮有人對(duì)中國(guó)的早期生物技術(shù)/醫(yī)藥技術(shù)感興趣，而他就成了這少數(shù)人之一，并且在與數(shù)家極具發(fā)展?jié)摿Φ墓竞献髦螅菬崆楦邼q。

世界發(fā)現(xiàn)中國(guó)生物技術(shù)

2007年8月，無(wú)錫姚明康德上市了，緊隨其后的是其他幾家中國(guó)生物技術(shù)企業(yè)的首次公開(kāi)募股。整個(gè)世界突然意識(shí)到中國(guó)也有生物技術(shù)產(chǎn)業(yè)，并想了解更多，然后開(kāi)始紛紛涌至中國(guó)。2008年初，我們搬到了對(duì)面更大的辦公室，公司團(tuán)隊(duì)也從2名擴(kuò)大到10名全職和數(shù)名兼職員工。Scott先生還接受了中央電視臺(tái)英文國(guó)際頻道及幾家電臺(tái)和互聯(lián)網(wǎng)節(jié)目的采訪。

到2010年底， ChinaBio? 已經(jīng)在中國(guó)舉辦了的15次重大會(huì)議，包括10次ChinaBio?創(chuàng)業(yè)投資論壇和兩屆ChinaBio?合作論壇，并在舊金山和布魯塞爾舉辦參會(huì)人數(shù)近4000人的“中國(guó)節(jié)”活動(dòng)。2011年我們計(jì)劃主辦5次主要會(huì)議，包括我們的首屆ChinaBio? 領(lǐng)導(dǎo)人高爾夫年會(huì)。（詳情參見(jiàn)“會(huì)議預(yù)告”欄目）

我們與一些包括羅氏、輝瑞及Life Technologies在內(nèi)的全球最具影響力的醫(yī)藥和生物技術(shù)公司進(jìn)行了合作，幫助中國(guó)生物醫(yī)藥公司融資逾4億美元。我們的公司內(nèi)部調(diào)研團(tuán)隊(duì)密切追蹤中國(guó)生物技術(shù)行業(yè)的商業(yè)動(dòng)態(tài)，包括新技術(shù)研發(fā)、臨床實(shí)驗(yàn)活動(dòng)、風(fēng)險(xiǎn)投資、并購(gòu)及首募活動(dòng)等。這些信息幫助我們和我們的客戶(hù)深入了解行業(yè)發(fā)展動(dòng)向并準(zhǔn)確預(yù)測(cè)中國(guó)對(duì)未來(lái)全球生物醫(yī)藥產(chǎn)業(yè)的影響。 

Scott先生已經(jīng)是以上海為家，樂(lè)享中國(guó)的無(wú)限活力而放棄圣地亞哥的陽(yáng)光和沙灘。中國(guó)的事務(wù)發(fā)展之快仍讓他驚喜不已。

It Begins with a Vacation

The story of ChinaBio? starts with a vacation... In November 2006, our founder, Greg Scott, visited China for the first time.  He had arranged to have one business meeting while he was in Shanghai at Zhangjiang Hi-Tech Park.  From that single meeting, and a brief tour of the 25 sq. km Park where he saw Roche, Pfizer, GSK, Lilly, and over 200 early-stage biotech companies, he knew he would be coming back to China.  His 10-years of experience as an angel investor in biotech in the US led him to believe that there was something "big" happening in China, and he had to find out more.

So in late January 2007, he returned for one week with only two scheduled meetings.  By the end of the week and over 30 meetings, the seeds of ChinaBio? were sown.  By April, ChinaBio's offices were open in the Biotech VC Plaza building in Zhangjiang Hi-Tech Park, and the first staff was hired.  While often told he was one of the very few interested in early-stage biotech/medtech in China, his interest remained high as he worked with several promising companies.

The World Discovers China Biotech

Then, in August 2007, WuXi PharmaTech went public, quickly followed by several other China biotech IPOs.  Suddenly the world knew there was a biotech industry in China and wanted to know more and began beating a path to ChinaBio's door. By early 2008, ChinaBio had moved to larger offices and expanded the staff from two to six full time and three part time members.  Mr. Scott had also been interviewed on CCTV and several radio and internet shows.

By the end of 2010, ChinaBio? had organized over 15 major conferences in China, including 10 ChinaBio? Investor Forums, two ChinaBio? Partnering Forums, and China Day events in San Francisco and Brussels, hosting a combined total of nearly 4000 attendees.  For 2011, ChinaBio is planning five major events, including our new ChinaBio?Leadership Retreat.  (See .)

ChinaBio? has also worked with some of the world's most respected life science companies, including Pfizer, Roche Diagnostics and Life Technologies, and helped China biomedical companies raise over $400M US.  Our in-house research team tracks China's biotech industry including novel technology development, clinical trial activity, VC investments, IPOs and M&A and partnering activity.  This information gives us and our clients critical insights into the direction of the industry and how China will impact the future of the global biopharma industry.

Mr. Scott now makes Shanghai his home, trading the sunshine and beaches of San Diego for the vitality of China.  It surprises even him how quickly things can move in China.